Edition:
United States

People: Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

4.55USD
3:30pm EDT
Change (% chg)

$-0.10 (-2.26%)
Prev Close
$4.65
Open
$4.64
Day's High
$4.69
Day's Low
$4.38
Volume
7,996,220
Avg. Vol
6,123,964
52-wk High
$7.15
52-wk Low
$2.50

Jacob, Gary 

Dr. Gary S. Jacob, Ph.D. is a Chairman of the Board, President, Chief Executive Officer of the Company. He served as our President, Chief Executive Officer and a Director since July 2008 and as Chairman since September 2013. Since May 2013, Dr. Jacob has also been serving as Chairman of our previously wholly-owned subsidiary, ContraVir Pharmaceuticals, Inc., a biopharmaceutical drug development company and was Chief Executive Officer of ContraVir from May 2013 until March 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob currently serves as a director of Trovagene, Inc., a diagnostics company. Dr. Jacob has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England. Dr. Jacob’s broad management expertise in the pharmaceutical and biotechnology industries provides relevant experience in a number of strategic and operational areas and led to the Board’s conclusion that he should serve as a director of our company.

Basic Compensation

Total Annual Compensation, USD 800,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,411,680
Fiscal Year Total, USD 4,211,680

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gary Jacob

4,211,680

Marino Garcia

--

Patrick Griffin

1,195,750

Troy Hamilton

1,362,920

Bernard Denoyer

707,434

Kunwar Shailubhai

1,584,540
As Of  30 Dec 2015